Leveraging Age and Comorbidity to Optimize Treatment Selection in Men with Recurrent Prostate Cancer

Abstract

Men with biochemical recurrence (BCR) after definitive therapy for prostate cancer are often treated with early androgen deprivation therapy (ADT) despite a lack of clear evidence of survival benefit. Early ADT is especially risky for older men or those with multiple comorbidities, since it significantly increases risk of cardiovascular mortality in these men. Moreover, as the putative survival advantage associated with early ADT is not realized for many years, for older and sicker men, it is likely that any survival benefit of early ADT is markedly attenuated due to limited longevity. Though an argument could be made for delaying hormonal therapy in these men (especially those with favorable tumor risk), this has yet to be realized due to lack of compelling data.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Dec 01, 2021
Accession Number
AD1210816

Entities

People

  • Timothy Daskivich

Organizations

  • Cedars-Sinai Medical Center

Tags

DTIC Thesaurus Topics

  • Abstracts
  • Androgens
  • Biomedical Research
  • Cardiovascular Diseases
  • Comorbidity
  • Data Analysis
  • Databases
  • Department Of Defense
  • Deprivation
  • Diseases
  • Education
  • Health Services
  • Heart Diseases
  • Hospitals
  • Information Science
  • Lymph Nodes
  • Medical Personnel
  • Myocardial Ischemia
  • Neoplasms
  • Propensity Score Matching
  • Prostate
  • Prostate Cancer
  • Statistical Analysis
  • Therapy

Fields of Study

  • Medicine

Readers

  • Mental Health of Military Veterans with Posttraumatic Stress Disorder (PTSD): Risk Factors, Prevalence, Symptoms, and Treatment.
  • Molecular Biology and Genetics
  • Systems Analysis and Design